TandemAI, a Boston- and New York–based AI-powered, end-to-end drug discovery company, has secured a $22 million Series A extension.
Investors
The round included participation from both new and existing investors, including V-Capital and KHK Fund.
TandemAI Use of Funds
The funding will support continued development of AI and physics-based models across multiple drug modalities and will expand wet-lab capacity to meet growing client demand.
About TandemAI
Founded in 2021, TandemAI is a company dedicated to transforming drug discovery by integrating generative AI, physics-based modeling (molecular dynamics and quantum mechanics), its next-generation AI-powered SaaS platform TandemViz™, and large-scale chemistry and biology labs. The SaaS platform unifies advanced computational tools, HPC infrastructure, and data management to overcome key research and development bottlenecks. TandemAI has established partnerships with four of the world’s top ten global pharmaceutical companies and built a network of over 150 industry partners.
Funding Details
Company: TandemAI
Raised: $22.0M
Round: Series A Extension
Funding Date: November 2025
Investors: V-Capital, KHK Fund
Company Website: https://tandemai.com/
Software Category: AI Drug Discovery / Computational Drug Development
Source: https://www.businesswire.com/news/home/20251113520060/en/